Pdac
A topic on our watch list — we track its coverage across 2 domains, including Pubmed Targeted and Industry News.
If Pdac is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- A ternary association of KRas, EphA2 and integrins controls PDAC cell behaviour. · J Biol Chem · 2026-08-10
- Andrea Wang-Gillam Highlights the Advancement of JAB-23E73 in Frontline PDAC · OncoDaily · 2026-07-20
- CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC. · EMBO J · 2026-07-11
- Evolutionarily conserved epigenetic regulation of transcriptional cell states during vertebrate pancreatic tumorigenesis. · Cell Mol Gastroenterol Hepatol · 2026-08-14
- Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer · OncoDaily · 2026-08-13
- Daraxonrasib Resistance in Pancreatic Cancer Points to New Combination Strategies · OncoDaily · 2026-08-12
What the reporting says
It shows up alongside KRAS (18), Pancreatic Cancer (15).
Two steps out: Colorectal Cancer (through KRAS, 18 shared stories on the weaker link); G12d (through KRAS, 18 shared stories on the weaker link); Braf (through KRAS, 17 shared stories on the weaker link); Immunotherapy (through KRAS, 17 shared stories on the weaker link).
Tracked since Apr 8, with coverage on 21 separate days — concentrated in Pubmed Targeted and Oncology.